Lynk Pharmaceuticals Reports Positive Long-Term Phase III Results for Zemprocitinib in bDMARDs-Inadequate Responders with Moderate-to-Severe Rheumatoid Arthritis

Lynk Pharmaceuticals announced positive long-term results from a pivotal Phase study. The provided article excerpt does not specify the treatment, results, numerical data, or study details, so the magnitude and potential implications cannot be assessed.